A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA, Thalmann GN, Lucca I, Kwiatkowski M, Wirth GJ, Strebel RT, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Torpai R, Bubendorf L, Wicki A, Roth B, Bosshard P, Püschel H, Boll DT, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Hayoz S.
Rentsch CA, et al. Among authors: puschel h.
Eur Urol Oncol. 2022 Apr;5(2):195-202. doi: 10.1016/j.euo.2021.12.006. Epub 2022 Jan 7.
Eur Urol Oncol. 2022.
PMID: 35012889
Clinical Trial.